Skip to main content
Download PDF

Genetic association of Interleukin-17A polymorphism in Bangladeshi patients with breast and cervical cancer: a case-control study with functional analysis

BMC Cancer volume 24, Article number: 660 (2024) Cite this article

Abstract

Background

Breast and cervical cancer are the two leading cancers in terms of incidence and mortality. Previous studies reported different interleukins, including interleukin-17A (IL-17A) to be responsible for the development and progression of these malignancies. Therefore, we speculated that the variants in this gene might be associated with these cancer developments in Bangladeshi population. For evaluating the hypothesis, we investigated the association of IL-17A rs3748067 polymorphism with the susceptibility of both breast and cervical cancer.

Methods

This case-control study was performed on 156 breast cancer patients, 156 cervical cancer patients, and 156 controls using the tetra-primer amplification refractory mutation system-polymerase chain reaction. The statistical software package SPSS (version 25.0) was applied for analyses. The genetic association was measured by the odds ratio (OR) and 95% confidence intervals (CIs). A statistically significant association was considered when p-value ≤ 0.05. Functional analysis was performed using GEPIA and UALCAN databases.

Results

From the calculation of the association of IL-17A rs3748067 with breast cancer, it is found that no genotype or allele showed a statistically significant association (p>0.05). On the other hand, the analysis of IL-17A rs3748067 with cervical cancer demonstrated that CT genotype showed a significant association (CT vs. CC: OR=1.79, p=0.021). In the overdominant model, CT genotype also revealed a statistically significant association with cervical cancer, which is found to be statistically significant (OR=1.84, p=0.015).

Conclusion

Our study summarizes that rs3748067 polymorphism in the IL-17A gene may be associated with cervical cancer but not breast cancer in Bangladeshi patients. However, we suggest studies in the future with a larger sample size.

Peer Review reports

Background

Breast cancer became the leading cancer worldwide in 2020, with a reported 2.3 million new cases representing 11.7% of total cancer incidence. In terms of mortality, breast cancer is the fifth leading causes of mortality globally, with approximately 685,000 deaths [1,2,3]. Cervical cancer, in contrast, is the fourth most diagnosed malignancy and also the fourth major cause of mortality in females. In 2020 alone, about 604,000 new cervical cancer cases and 342,000 deaths were reported. Moreover, cervical cancer was found to be one of the top three cancers that affect females under the age of 45 in 146 countries, which accounts for 79% in 185 countries assessed [2, 4].

Patients’ age, reproductive and hormonal factors (first birth or menarche at early age, fewer children, less breastfeeding, menopause at later age, menopausal hormone therapy, and oral contraceptives), personal or family history, genetic predisposition, environmental factors, and lifestyle factors (alcohol consumption, excessive body weight, and physical inactivity) have been correlated with an elevated risk for the development and progression of breast cancer [5,6,7]. Again, risk factors of cervical malignancy include both behavioral (sexual activity and lifestyle factors) and certain infectious (human papillomavirus) contributors [8]. Other risk factors are age at the first full-term pregnancy, diet, family history, immunosuppression, immune deficiency, oral contraceptives, parity, and smoking [9,10,11].

Interleukin-17 A (IL-17A) is one of the most intensively investigated interleukins from the IL-17 family which play a critical function in cancer development, progression, and control [12, 13]. It is found in the human chromosome 6.12.2 and encodes a 155 amino acid containing protein (consisting of signal peptide with 23 amino acids and a mature peptide with 132 amino acids) [14]. In carcinogenesis, IL-17A has been reported to engage myeloid-derived suppressor cells (MDSCs) that repress anti-tumor activity [15, 16]. IL-17A could also stimulate unnecessary tumor growth by influencing IL-6, which in turn activates tumorigenic signal transducer and activator of transcription (STAT3) signaling pathway and over-express genes associated with pro-survival and pro-angiogenesis [17].

Numerous studies have reported a higher expression of IL-17A in tumor cells, including breast cancer, colorectal carcinoma, gastric carcinoma, hepatocellular carcinoma, ovarian cancer, medulloblastoma, pancreatic cancer, non-small-cell lung cancer, and thyroid cancer [18, 19]. Polymorphisms in the IL-17A gene have been investigated over time to find the possible association with cancers. A major single nucleotide polymorphism (SNP) in the IL-17A gene is rs3748067 which is found on the 3’-untranslated regions (UTR) in chromosome 6 location 52,190,541. The association of r3748067 polymorphism with various cancers has been extensively evaluated in the last decade that includes breast cancer [20], cervical cancer [21,22,23,24,25,26], colorectal cancer [27, 28], gastric cancer [29, 30], lung cancer [31], and others.

Although previous studies have evaluated the correlation of IL-17A gene rs3748067 polymorphism with the susceptibility of breast and cervical cancers, the results were incosistent. Besides, no study has been performed in Bangladeshi breast and cervical cancer patients to evaluate the association of rs3748067 polymorphism. Therefore, we conducted the present case-control study to analyze the association of the common SNP in the IL-17 A (rs3748067) gene with the susceptibleness of breast and cervical cancer.

Methods

Study settings

The reporting of the present retrospective case-control analysis conforms to the latest STROBE guidelines designed for case-control studies [32]. In this study, we recruited two groups of patients: one group with breast cancer and another group with cervical cancer. Both groups consisted of 156 patients, each of whom was appointed randomly from the National Institute of Cancer Research and Hospital (NICRH) during the period from July 2019 to June 2020. Again, for the control arm, we recruited 156 healthy volunteers, who visited the NICRH during the time of patient recruitment by matching their age and sex with the breast and cervical cancer patients. A predesigned study protocol and a consent form were used for the clinical investigation of breast and cervical cancer patients. Ethical permissions were obtained from the NIRCH (for breast cancer: NICRH/Ethics/2019/446 and for cervical cancer: NICRH/Ethics/2019/447) ethics committee. We used a standard questionnaire for collecting the details of the patients, including their sociodemographic details, clinicopathological history, and present status. Sociodemographic details of the controls were also recorded. We have selected patients who were free from other comorbidities such as liver, lung, and kidney diseases. This study was conducted at the Laboratory of Pharmacogenomics and Molecular Biology located at the Department of Pharmacy, Noakhali Science and Technology University.

Blood sample collection and DNA extraction

Each participant included in this case-control study donated about 3 ml of blood. The blood samples were collected via a 3 ml intact syringe and transferred immediately into an ethylene diamine tetra acetic acid (EDTA) containing plastic tube. The tubes were then stored in a -80ºC refrigerator until processed. The extraction of genomic DNA from whole blood was completed following the DNA extraction method described by Islam and colleagues [33] using a DNA extraction kit provided by Favorgen (Taiwan). The purity of extracted DNA was assessed by keeping the absorbance ratio A260:A280 and samples with a ratio of > 1.5 were considered pure DNA.

Primer design and genotyping

There are different online-based software available for designing primers. We have used the Primer1 software to design four required primers. For genotyping process, the tetra-primer amplification refractory mutation system–polymerase chain reaction (T-ARMS–PCR) was utilized as described by Aziz and colleagues [34]. To validate the method, we first carried out a gradient PCR at temperatures ranging from 60°C to 65°C by a continuous alteration of primer concentration and MgCl2 concentration. After completing multiple PCRs, the intended PCR products for IL-17A rs3748067 were found at the temperature of 65°C. The genotyping of all samples was completed using the same formula of the PCR working master mix at the temperature of 65°C and visualized using ethidium bromide-stained 1.5% gel electrophoresis. The details of primers and conditions are listed in Table 1, and the agarose gel images are shown in Fig. 1 (breast cancer samples) and Fig. 2 (cervical cancer samples). For controlling the quality of genotyping and ensuring repeatability, 20% of the samples were randomly assessed.

Table 1 Primer sequences and PCR conditions with observed products
Full size table
Fig. 1
figure 1

PCR products for IL-17A rs3748067 in breast cancer after 1.5% agarose gel electrophoresis

Full size image
Fig. 2
figure 2

PCR products for IL-17A rs3748067 in cervical cancer after 1.5% agarose gel electrophoresis

Full size image

Statistical analysis

The sociodemographic and clinicopathological characteristics were reported as percentages. The genotypes and allele frequencies were measured for the deviation from the Hardy-Weinberg equilibrium (HWE) by applying the χ2-statistic. The link of IL-17A gene rs3748067 polymorphism with breast and cervical cancer was calculated by logistic regression according to five genotypic models (additive model 1, additive model 2, dominant model, recessive model, and overdominant model) and allele model using odds ratio (OR) with 95% confidence intervals (CI). Best-fit model was determined using Akaike’s information criterion (AIC) and Bayesian information criterion (BIC) values. A statistically significant risk was considered in terms of p-value ≤ 0.05. Statistical calculations were done by the use of latest SPSS software version 25 (IBM Corp., Armonk, NY, USA).

Functional analysis

The Gene Expression Profiling Interactive Analysis (GEPIA) (available at http://gepia.cancer-pku.cn) is a recently developed interactive web resource. It is utilized for examining the RNA sequencing expression data of 9,736 tumors and 8,587 normal tissues retrieved from The Cancer Genome Atlas (TCGA) along with the Genotype-Tissue Expression (GTEx) applying a standard processing pipeline. In this study, GEPIA was applied to evaluate the transcriptional level of the IL-17A gene expression of breast and cervical cancer tissues versus normal tissues and visualized using box plots. Hub genes with |Log2FC| ≥ 1 as well as p ≤ 0.05 were considered statistically significant. Again, the UALCAN is a comprehensive interactive web server for investigating cancer OMICS data [35]. We have used this webserver to show the IL-17A expression based on the sample types, patient’s age, individual cancer stages, patient’s race, weight, and tumor grade for both breast and cervical cancer.

Results

Characteristics of participants

The distribution of characteristic variables of breast cancer patients and healthy subjects is listed in Table 2. It is found that 40.38% of patients were under 45 years old and 46.15% were between 45 and 60 years. In comparison with cases, controls consisted of 50.64% under 45 years, and 43.58% were between 45 and 60 years. The average age of the breast cancer patients and controls was 45.37 years and 40.02 years, respectively. Besides, the average body mass index (BMI) was 28.61 kg/m2 and 22.57 kg/m2 in the patient group and control group, respectively. About 97.44% of cases were married, and 92.95% of controls were married. Of the patients, 61.21% had invasive duct cell carcinoma and most of the patients had grade II breast cancer consisting of 65.45%. Around 56.83%, 41.01%, 22.30%, 19.42%, and 17.27% of patients have been diagnosed by USG, biopsy, CT, FNAC, and X-ray, respectively. Almost half of the patients received surgery and around 71% of patients received 4–8 cycles of chemotherapy. Patients with negative hormonal status were prevalent such as 34.88% were ER (-), 34.11% were PR (-), and 39.53% were HER2 (-).

Table 2 Distribution of characteristic variables of breast cancer patients and controls
Full size table

The detailed characteristics of cervical carcinoma patients and healthy subjects are summarized in Table 3. As the data show, about 48.08% of patients were under 45 years old and 39.74% were between 45 and 60 years. The average age of cervical malignancy patients was 41.12 years, and the average BMI was 26.93 kg/m2. Approximately 94.87% of cases were married. The menstruation cycle starting age of 86.43% of patients was ≤ 13 years, whereas 90.28% of controls had their first menstruation cycle at ≤ 13 years. Again, the age of menstruation cycle stopping of 77.61% of patients was ≤ 45 years compared to 68.33% of the controls. Almost 80% of patients conceived their first child before or under 18 years, whereas 75.73% of controls gave birth to their first child at this age. The history of contraceptives shows that 75.64% of cervical cancer patients took pills and 63.56% of them took the pill for less than or equal to 5 years. Around 85% of cervical cancer patients had squamous cell carcinoma, and most of the patients were at IIB (56.55%) tumor stage, while 68.59% had grade 2 cancer and 55.13% were with T1 tumor size. 83.33% of patients were with negative (+) lymph nodes, and the status of distant metastasis showed that 68.42% of patients were in Mx state.

Table 3 Distribution of characteristic variables of cervical cancer patients and controls
Full size table

Distribution of genotypes of rs3748067

The frequency of genotypes in breast cancer patients obeyed HWE (χ2 = 2.85, p-value = 0.091) with a minor allele frequency of 20.51%. In controls, the genotype distribution did not show any deviation from HWE (χ2 = 3.46, p-value = 0.063) and minor allele frequency was 17.31%. The distribution of genotypes in cervical cancer patients also showed no departure from HWE (χ2 = 2.05, p-value = 0.152) and the frequency of minor allele was 21.15%, as shown in Table 4.

Table 4 Distribution of genotypes of IL-17 A rs3748067 in breast and cervical cancer cases and controls
Full size table

Association between IL-17A rs3748067 variant with breast cancer

Table 5 presents the association analysis of IL-17 A gene rs3748067 polymorphism with breast cancer. From the analysis, it is found that additive model 1 and additive model 2 showed increased risk but the associations were not statistically significant (CT vs. CC: OR = 1.25, p = 0.394; TT vs. CC: OR = 1.35, p = 0.545, respectively). Other genotype models, such as dominant, recessive, and over-dominant models, also showed a similar nonsignificant association (CT + TT vs. CC: OR = 1.26, p = 0.332; OR = 1.27, p = 0.628; OR = 1.22, p = 0.441, respectively). In the allele model, minor allele T showed an enhanced risk association, and the association is not statistically significant (T vs. C: OR = 1.23, p = 0.307).

Table 5 Association of rs3748067 polymorphism with breast and cervical cancer
Full size table

Association between IL-17A rs3748067 variant with cervical cancer

The correlation of IL-17A gene rs3748067 polymorphism with cervical cancer susceptibility (Table 5) demonstrated that two genetic association models, i.e., additive model 1 and over dominant model, showed a statistically significant association with cervical cancer (CT vs. CC: OR = 1.79, 95% CI = 1.09 to 2.92, p = 0.021; OR = 1.84, 95% CI = 1.13 to 3.00, p = 0.015). Other models did not show any significant association with cervical cancer (Additive model 2- TT vs. CC: OR = 0.58, p = 0.394; Dominant model - CT + TT vs. CC: OR = 1.58, p = 0.052; Recessive model: TT vs. CC + CT: OR = 0.49, p = 0.248; Allele model: T vs. C: OR = 1.28, p = 0.223).

Comparison of genotypes and risk association between breast and cervical cancer

The frequency of genotypes of IL-17 A rs3748067 and their comparison between breast cancer and cervical cancer patients are given in Fig. 3. It is observed that CC homozygote frequency (CC = 102) is higher in breast cancer patients than in cervical cancer patients (CC = 94). The distribution of CT heterozygote and TT mutant homozygotes shows that the frequencies of CT genotypes are higher, but TT genotypes are lower in cervical cancer patients (CT = 44 vs. 58 and TT = 10 vs. 4).

Fig. 3
figure 3

Comparison of genotypes of IL-17 A rs3748067 between breast and cervical cancer

Full size image

Besides that, the comparison of ORs for analyzing the risk association of IL-17A rs3748067 between breast and cervical cancer patients (Fig. 4) showed that the ORs were higher for two genetic association models of cervical cancer- additive model 1 and overdominant model compared to breast cancer (1.79 vs. 1.25 and 1.84 vs. 1.22, respectively) and associations were also statistically significant. Although other genetic models in breast cancer showed higher ORs than in cervical cancer, except for the allele model, these models were not statistically significant. The model that produced the lowest values of AIC and BIC was deemed to be the optimal fit. It may be that the recessive model would be the most suitable choice for breast cancer, although no significant association was found, whereas, in the case of cervical cancer, the overdominant model is the best-fit model (Table 5).

Fig. 4
figure 4

Comparison of risk association models of IL-17A rs3748067 between breast and cervical cancer population

Full size image

IL-17A transcription levels

The level of IL-17A transcription in breast and cervical cancer tissues versus normal tissues is visualized in Fig. 5. The box plots indicated that there is a significantly greater expression of IL-17 A in cervical carcinoma (CESC) tissues than in normal tissues. The expression level in breast carcinoma (BRCA) tissues and normal tissues was not statistically significant.

Fig. 5
figure 5

IL-17A gene expression of breast and cervical cancer tissues versus normal tissues based on the GEPIA (http://gepia.cancer-pku.cn)

Full size image

The IL-17A expression based on sample types, patient’s age, individual cancer stages, patient’s race, weight, and tumor grade from the UALCAN web server for cervical cancer and breast cancer is depicted in Fig. 6 and Supplementary Fig. 1, respectively. The expression of IL-17A was found to be higher in cervical tumor samples (Fig. 6a), 81–100 years of age (Fig. 6b), cancer stage 1 and stage 2 (Fig. 6c), African American patients (Fig. 6d), obese and extremely obese patients (Fig. 6e), and tumor grade 2 and grade 3 patients (Fig. 6f). Again, in terms of breast cancer, no significant expression change was observed for sample types, patient’s age, cancer stages, patient’s race, and gender (Supplementary Fig. 7a-e) except for the medullary subtype (Supplementary Fig. 7f).

Fig. 6
figure 6

IL-17A expression based on the sample types, patient’s age, individual cancer stages, patient’s race, weight, and tumor grade of cervical cancer

Full size image

Discussion

Breast and cervical cancers are the two most commonly diagnosed malignancies in females worldwide [1, 2]. Cytokines have been playing an indispensable role in tumor growth and progression. IL-17A is considered one of the most common cytokines from the IL-17 family that has been extensively studied due to its prominent role in carcinogenesis, especially in cervical and breast carcinoma besides inflammation [36]. A plethora of studies have described that IL-17A protein is greatly expressed within tumor tissues: for instance, gastric carcinoma, breast cancer, ovarian cancer, colorectal carcinoma, lung cancer, thyroid cancer, and hepatocellular carcinoma [18, 19]. Again, the increased IL-17A levels in the blood are linked with the aggressiveness of pancreatic adenocarcinoma, non-small cell lung cancer, thyroid tumors, laryngeal squamous cell carcinoma, and colorectal carcinoma [37,38,39,40]. In addition, previous studies with rs3748067 variant in the IL-17A gene described its notable association with a variety of cancers in multiple ethnicities, such as breast cancer [20], cervical cancer [21,22,23,24,25,26], colorectal cancer [27, 28, 41], gastric cancer [29, 30], and others. Based on the previous research, we performed this case-control study that reported the correlation of IL-17A rs3748067 polymorphism with the risk of cervical malignancy.

From the analysis in this study, we did not find any significant association of IL-17 A rs3748067 polymorphism with breast carcinoma in the studied population. However, our study found a higher frequency of the major allele C (79.49%) compared to the minor T allele (20.51). Again, the frequency of CC homozygous genotype was also greater (65.38%) than the heterozygous or mutant homozygous genotypes. The only previous study with this polymorphism in breast cancer also described similar findings. The study by Wang et al. (2012) showed no notable link between IL-17A gene rs3748067 variant and breast carcinoma in a Chinese case-control study in females. They also reported a higher frequency of a major allele (G allele) in their studied population [20]. To further explore the role of IL-17A in breast carcinoma, we analyzed the expression level in breast carcinoma (BRCA) tissues and normal tissues that were not statistically significant. Moreover, we did not observe any significant expression of IL-17A in terms of sample types, cancer stages, patient age, patient race, and gender.

Our study revealed a statistically significant link between IL-17A gene rs3748067 variant and cervical cancer. Our analysis demonstrated that CT genotype (OR = 1.79, p = 0.021) and over-dominant model (OR = 1.84, p = 0.015) are significantly correlated with cervical carcinoma risk. Besides, the frequency of the major allele (C allele: 78.85%) is greater than the minor allele (T allele: 21.15%). Moreover, we found that there is a significantly greater transcription level of IL-17A in cervical carcinoma (CESC) tissues than in normal tissues. The level of IL-17A expression was found to be higher in cervical tumor samples, 81–100 years of age, African American patients, obese and extremely obese patients, cancer stage 1 and stage 2, and in patients with tumor grade 2 and grade 3.

The correlation between IL-17A gene rs3748067 variant and breast carcinoma was examined for the first time in 2012 by Wang and colleagues [20] in Chinese Han women. The study recruited 491 breast cancer patients and 502 healthy individuals, and for genotyping, applied the SNaPshot technique. The study revealed that rs3748067 GG genotypes percentage was lower in PR-positive cases and was significantly correlated with PR hormonal status. They concluded that rs3748067 GG genotypes might be linked to poor prognosis and ineffective treatment. The link of this variant was not studied later in any other population. IL-17A rs3748067 has been studied in cervical cancer several times. The correlation was also evaluated in Chinese women by Niu et al. [22]. They explicated that subjects with the TT genotype and T allele were more prone to cervical carcinoma [22]. Another study in the Chinese population examined the contribution of rs3748067 in 352 cervical malignancy patients and 352 healthy controls using the PCR-RFLP method. However, they failed to establish any association between this polymorphism with cervical cancer [25]. Some other studies also failed to establish the association of rs3748067 variant with cervical carcinoma [24, 26].

The latest meta-analysis with rs3748067 variant in the IL-17A gene reported that it was correlated with cervical carcinoma, with T allele carriers depicting an enhanced risk [21]. Another meta-analysis conducted by Yang and colleagues [23] reported an elevated susceptibility of cervical carcinoma due to this polymorphism.

In this study, we have also tried to compare the frequency of genotypes of IL-17A rs3748067 between breast and cervical cancer patients. We have found that the frequency of CC homozygotes is greater in breast cancer patients than in cervical cancer patients. The distribution of CT heterozygote and TT mutant homozygotes reveals that the percentage of CT genotypes is higher, but TT genotypes are lower in cervical cancer patients. In addition, the comparison of ORs between breast and cervical cancer patients showed that the ORs were significantly higher for additive model 1 and the over-dominant model in cervical cancer compared to breast cancer.

It is to be mentioned that there are some limitations of the present study, such as the total number of participants included in the study is relatively low. Besides, all sociodemographic and clinicopathologic details of the participants were not possible to collect, which may alter the association. In addition, for this study, we have selected only available SNP from the public electronic database. However, our study has identified the link of IL-17A rs3748067 variant with cervical carcinoma and we are hopeful that our findings will have an impact on further studies that may result in stronger evidence. Besides these, possible interactions between the susceptibility loci and these risk factors should be thoroughly investigated.

Conclusion

This study concludes that rs3748067 polymorphism in the IL-17A gene is associated with cervical cancer, not breast cancer in Bangladeshi patients. However, we suggest studies in the future with a larger sample size.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request. The details data cannot be shared publicly due to the restriction of the ethical committee.

Abbreviations

IL-17A:

Interleukin-17 A

SNP:

Single nucleotide polymorphism

MDSCs:

Myeloid-derived suppressor cells

STAT3:

Signal transducer and activator of transcription

NICRH:

National Institute of Cancer Research and Hospital

EDTA:

Ethylene diamine tetra acetic acid

T-ARMS:

Tetra-primer amplification refractory mutation system

PCR:

Polymerase chain reaction

HWE:

Hardy-Weinberg equilibrium

OR:

Odds ratio

CI:

Confidence intervals

GEPIA:

Gene Expression Profiling Interactive Analysis

TCGA:

The Cancer Genome Atlas

GTEx:

Genotype-Tissue Expression

References

  1. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021. https://doi.org/10.1002/ijc.33588.

    Article  PubMed  Google Scholar 

  2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

    Article  PubMed  Google Scholar 

  3. Aziz MA, Jafrin S, Islam MS, Kabir Y. Interleukins in the development and progression of breast Cancer. In: Interdisciplinary Cancer Research. Cham: Springer; 2022. p. 1–22.

    Google Scholar 

  4. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191-203.

    Article  PubMed  Google Scholar 

  5. Jafrin S, Aziz MA, Anonna SN, Akter T, Naznin NE, Reza MS, Islam MS. Association of TP53 codon 72 arg > pro polymorphism with breast and lung cancer risk in the south Asian population: a meta-analysis. Asian Pac J Cancer Prev. 2020;21(6):1511–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol. 2014;5(3):283–98.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Fakhri N, Chad MA, Lahkim M, Houari A, Dehbi H, Belmouden A, El Kadmiri N. Risk factors for breast cancer in women: an update review. Med Oncol. 2022;39:12–197.

    Article  Google Scholar 

  8. Barek MA, Basher MA, Aziz MA, Hossen MS, Jahan N, Afroz N, Begum M, Jafrin S, Uddin MS, Millat MS, Hoque MM, Islam MS. Assessment of the association of CYP1A1 gene polymorphisms with the susceptibility of cervical cancer: a case-control study and meta-analysis. Heliyon. 2023;9(7): e17712.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Muhammad SB, Hassan F, Bhowmik KK, Millat MS, Sarwar MS, Aziz MA, Barek MA, Uddin MS, Ferdous M, Islam MS. Detection of association of IL1β, IL4R, and IL6 gene polymorphisms with cervical cancer in the Bangladeshi women by tetra-primer ARMS-PCR method. Int Immunopharmacol. 2021;90:107131.

    Article  CAS  PubMed  Google Scholar 

  10. Ivy SC, Shabnaz S, Shahriar M, Jafrin S, Aka TD, Aziz MA, Islam MS. Association of RAD51 and XRCC2 gene polymorphisms with cervical cancer risk in the Bangladeshi women. Asian Pac J Cancer Prev. 2021;22(7):2099–107.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Nazneen F, Millat MS, Barek MA, Aziz MA, Uddin MS, Jafrin S, Aka TD, Islam MS. Genetic polymorphism of miR-218-2 (rs11134527) in cervical cancer: a case-control study on the Bangladeshi women. MicroRNA. 2021;10(3):219–2246.

    Article  CAS  PubMed  Google Scholar 

  12. Briukhovetska D, Dörr J, Endres S, Libby P, Dinarello CA, Kobold S. Interleukins in cancer: from biology to therapy. Nat Rev Cancer. 2021;21(8):481–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010;129(3):311–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Krstic J, Obradovic H, Kukolj T, Mojsilovic S, Okic-Dordevic I, Bugarski D, Santibanez JF. An overview of Interleukin-17A and Interleukin-17 receptor a structure, interaction and signaling. Protein Pept Lett. 2015;22(7):570–8.

    Article  CAS  PubMed  Google Scholar 

  15. Chang SH, Mirabolfathinejad SG, Katta H, Cumpian AM, Gong L, Caetano MS, Moghaddam SJ, Dong C. T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci U S A. 2014;111(15):5664–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. He D, Li H, Yusuf N, Elmets CA, Li J, Mountz JD, Xu H. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol. 2010;184(5):2281–8.

    Article  CAS  PubMed  Google Scholar 

  17. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009;206(7):1457–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Tu JF, Pan HY, Ying XH, Lou J, Ji JS, Zou H. Mast cells comprise the Major of Interleukin 17-Producing cells and predict a poor prognosis in hepatocellular carcinoma. Med (Baltim). 2016;95(13): e3220.

    Article  CAS  Google Scholar 

  19. Carvalho DFG, Zanetti BR, Miranda L, Hassumi-Fukasawa MK, Miranda-Camargo F, Crispim JCO, Soares EG. High IL-17 expression is associated with an unfavorable prognosis in thyroid cancer. Oncol Lett. 2017;13(3):1925–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Wang L, Jiang Y, Zhang Y, Wang Y, Huang S, Wang Z, Tian B, Yang Y, Jiang W, Pang D. Association analysis of IL-17A and IL-17F polymorphisms in Chinese Han women with breast cancer. PLoS One. 2012;7(3): e34400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. de Moura EL, Dos Santos ACM, da Silva DM, Dos Santos BB, Figueredo DS, Moura AWA, da Silva AF, Tanabe ISB, de Lira Tanabe EL, Lira Neto AB, et al. Association of Polymorphisms in cytokine genes with susceptibility to precancerous lesions and cervical cancer: a systematic review with meta-analysis. Immunol Invest. 2021;50(5):492–526.

    Article  PubMed  Google Scholar 

  22. Niu AQ, Cao YH, Wang H, Zhang X, Zhu B, Li ZH. Role of IL17A rs2275913 and rs3748067 polymorphisms in the risk cervical cancer. Genet Mol Res. 2017;16(3). https://doi.org/10.4238/gmr16038826.

  23. Yang S, Li C, Li X, Huang X, Zhao Q, Liu D, Wu S. Relationship of IL-17A and IL-17F genetic variations to cervical cancer risk: a meta-analysis. Biomark Med. 2017;11(5):459–71.

    Article  CAS  PubMed  Google Scholar 

  24. Li L, Tian YL, Lv XM, Yu HF, Xie YY, Wang JD, Shi W. Association analysis of IL-17A and IL-17F polymorphisms in Chinese women with cervical cancer. Genet Mol Res. 2015;14(4):12178–83.

    Article  CAS  PubMed  Google Scholar 

  25. Cong J, Liu R, Wang X, Sheng L, Jiang H, Wang W, Zhang Y, Yang S, Li C. Association between interluekin-17 gene polymorphisms and the risk of cervical cancer in a Chinese population. Int J Clin Exp Pathol. 2015;8(8):9567–73.

    PubMed  PubMed Central  Google Scholar 

  26. Lv Q, Zhu D, Zhang J, Yi Y, Yang S, Zhang W. Association between six genetic variants of IL-17A and IL-17F and cervical cancer risk: a case-control study. Tumour Biol. 2015;36(5):3979–84.

    Article  CAS  PubMed  Google Scholar 

  27. Bedoui S, Dallel M, Barbirou M, Stayoussef M, Mokrani A, Mezlini A, Bouhaouala B, Almawi WY, Yacoubi-Loueslati B. Interleukin-17A polymorphisms predict the response and development of tolerance to FOLFOX chemotherapy in colorectal cancer treatment. Cancer Gene Ther. 2020;27(5):311–8.

    Article  CAS  PubMed  Google Scholar 

  28. Bedoui SA, Barbirou M, Stayoussef M, Dallel M, Mokrani A, Makni L, Mezlini A, Bouhaouala B, Yacoubi-Loueslati B, Almawi WY. Association of interleukin-17A polymorphisms with the risk of colorectal cancer: a case-control study. Cytokine. 2018;110:18–23.

    Article  CAS  PubMed  Google Scholar 

  29. Tian J, Liu G, Zuo C, Liu C, He W, Chen H. Genetic polymorphisms and gastric cancer risk: a comprehensive review synopsis from meta-analysis and genome-wide association studies. Cancer Biol Med. 2019;16(2):361–89.

    Article  PubMed  PubMed Central  Google Scholar 

  30. He B, Pan B, Pan Y, Wang X, Zhou L, Sun H, Xu T, Xu X, Liu X, Wang S. Polymorphisms of IL-23R predict survival of gastric cancer patients in a Chinese population. Cytokine. 2019;117:79–83.

    Article  CAS  PubMed  Google Scholar 

  31. He Y, Du Y, Wei S, Shi J, Mei Z, Qian L, Chen Z, Jie Z. IL-17A and IL-17F single nucleotide polymorphisms associated with lung cancer in Chinese population. Clin Respir J. 2017;11(2):230–42.

    Article  CAS  PubMed  Google Scholar 

  32. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. The strengthening the reporting of Observational studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–9.

    Article  Google Scholar 

  33. Islam MS, Ahmed MU, Sayeed MS, Maruf AA, Mostofa AG, Hussain SM, Kabir Y, Daly AK, Hasnat A. Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population. Clin Chim Acta. 2013;416:11–9.

    Article  CAS  PubMed  Google Scholar 

  34. Aziz MA, Akter T, Hussain MS, Millat MS, Uddin MS, Sajal M, Jafrin S, Aka TD, Akter T, Das C, et al. Association of rs363598 and rs360932 polymorphisms with autism spectrum disorder in the Bangladeshi children. Meta Gene. 2020;25: 100733.

    Article  Google Scholar 

  35. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, Varambally S. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Fabre J, Giustiniani J, Garbar C, Antonicelli F, Merrouche Y, Bensussan A, Bagot M, Al-Dacak R. Targeting the tumor microenvironment: the protumor effects of IL-17 related to cancer type. Int J Mol Sci. 2016;17(9): 1433.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Karabulut S, Afsar ÇU, Karabulut M, Alış H, Kılıc L, Çikot M, Yasasever CT, Aykan NF. Evaluation of serum Interleukin-17 (IL-17) levels as a diagnostic marker in pancreatic adenocarcinoma. J Gastrointest Cancer. 2016;47(1):47–54.

    Article  CAS  PubMed  Google Scholar 

  38. Karabulut S, Usul Afsar C, Karabulut M, Kilic L, Alis H, Kones O, Bilgin E. Faruk Aykan N. Clinical significance of serum interleukin-17 levels in colorectal cancer patients. J BUON. 2016;21(5):1137–45.

    PubMed  Google Scholar 

  39. Li FJ, Cai ZJ, Yang F, Zhang SD, Chen M. Th17 expression and IL-17 levels in laryngeal squamous cell carcinoma patients. Acta Otolaryngol. 2016;136(5):484–90.

    Article  CAS  PubMed  Google Scholar 

  40. Lu Y, Yuan Y. Serum level of interleukin-17 and interleukin-35 as a biomarker for diagnosis of thyroid cancer. J Cancer Res Ther. 2015;11(Suppl 2):C209-211.

    Article  PubMed  Google Scholar 

  41. Islam MR, Aziz MA, Shahriar M, Islam MS. Polymorphisms in IL-17A gene and susceptibility of colorectal cancer in Bangladeshi population: a case-control analysis. Cancer Control. 2022;29:10732748221143880.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We acknowledge the authority of the NICRH, Dhaka, Bangladesh, for their cooperation and help in the collection and primary storage of blood samples.

Funding

Noakhali Science and Technology University (NSTU) Research Cell (ID: NSTU/RC/20/C-84) and National Science and Technology (NST) Fellowship 2020, Ministry of Science and Technology, Bangladesh, have partially funded this research work.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Faculty of Science, Noakhali Science and Technology University, Noakhali, 3814, Bangladesh

    Md. Abdul Aziz, Subrina Chowdhury, Sarah Jafrin, Md Abdul Barek, Mohammad Sarowar Uddin, Md. Shalahuddin Millat & Mohammad Safiqul Islam

  2. Laboratory of Pharmacogenomics and Molecular Biology, Department of Pharmacy, Noakhali Science and Technology University, Noakhali, 3814, Bangladesh

    Md. Abdul Aziz, Sarah Jafrin, Md Abdul Barek, Mohammad Sarowar Uddin, Md. Shalahuddin Millat & Mohammad Safiqul Islam

  3. Bangladesh Pharmacogenomics Research Network (BdPGRN), Dhaka, 1219, Bangladesh

    Md. Abdul Aziz & Mohammad Safiqul Islam

Authors
  1. Md. Abdul Aziz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Subrina Chowdhury
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sarah Jafrin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Md Abdul Barek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohammad Sarowar Uddin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Md. Shalahuddin Millat
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mohammad Safiqul Islam
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MAA performed method validation, investigation, software, formal analysis, data curation, visualization, original draft preparation, review, and editing. SC and SJ contributed to formal analysis, review, and editing. MSU contributed to validation, investigation, and data curation. MAB and MSM contributed to writing, reviewing, and editing. MSI contributed to conceptualization, supervision, project administration, funding, software, resources, writing, review, and editing. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Mohammad Safiqul Islam.

Ethics declarations

Ethics approval and consent to participate

Ethical permissions were taken from the ethics committee of the National Institute of Cancer Research and Hospital (NIRCH) (for breast cancer: NICRH/Ethics/2019/446 and for cervical cancer: NICRH/Ethics/2019/447). In addition, written informed consent was obtained from all subjects before starting the study, and all procedures were conducted in accordance with the Helsinki Declaration.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aziz, M.A., Chowdhury, S., Jafrin, S. et al. Genetic association of Interleukin-17A polymorphism in Bangladeshi patients with breast and cervical cancer: a case-control study with functional analysis. BMC Cancer 24, 660 (2024). https://doi.org/10.1186/s12885-024-12352-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12885-024-12352-0

Keywords

BMC Cancer

ISSN: 1471-2407

Contact us